tbuckley/cabot-search huggingface dataset:
Reduction of Vein Graft Disease Using Photodynamic Therapy with Motexafin Lutetium in a Rodent Isograft Model
Authors: Atsushi Yamaguchi, Kathryn W. Woodburn, Motoya Hayase, Robert C. Robbins
Journal: Circulation (2000)

Background —Motexafin lutetium (Lu-Tex) is a photosensitizer that targets atheromatous plaque. Subsequent photoactivation (photodynamic therapy [PDT]) induces local cytotoxic effects. The aim of the present study was to investigate whether Lu-Tex targets vein graft intimal hyperplasia and whether subsequent photoactivation attenuates the disease process. Methods and Results —The subcellular localization of Lu-Tex and postillumination viability were studied in cultured human vein graft smooth muscle cells. Inferior vena cava–grafted rats were injected with Lu-Tex (10 mg/kg) 4 or 12 weeks after grafting. Biodistribution was assessed in a subgroup 24 hours after administration. Light therapy (742 nm) was performed 24 hours after Lu-Tex injection by illuminating intraperitoneally placed isografts using a laparotomy. Animals were divided into the following 4 groups: PDT (n=15), Lu-Tex injection and laparotomy (n=13), light treatment (n=14), and laparotomy only (n=13). Grafts were harvested 14 days after treatment for histochemical analysis. Lu-Tex localized within subcellular organelles of smooth muscle cells, and subsequent photoactivation induced cell death via apoptosis. The Lu-Tex concentrations present in the vein grafts were 9.3 times higher than those in the normal inferior vena cava. Postoperative PDT at 4 weeks after surgery significantly reduced the intima/media ratio, whereas treatment at 12 weeks did not reduce the intima/media ratio. Activated macrophages were observed 4 weeks after grafting; however, a significant reduction occurred in these cells by 12 weeks. The mechanism by which PDT works may be related to the presence of activated macrophages. Conclusions —PDT significantly reduces the intima/media ratio in the early phase of vein graft disease. Lu-Tex–mediated PDT may be a viable method for the attenuation of atherosclerotic disease in vein grafts.
Erratum: Vol. 65, Suppl. 3
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

In the report "Safe and Effective Deployment of Personnel to Support the Ebola Response-West Africa," which was part of the supplement entitled "CDC's Response to the 2014-2016 Ebola Pandemic-West Africa and United States," the following author was omitted from the listing on the first page: Jacqueline R. Burkholder, PhD, Division of Emergency Operations, Office of Public Health Awareness, CDC.
Hiroshima and ourselves
Authors: R. J. Lifton
Journal: JAMA (1985)

WE DO not quite know what to do with Hiroshima. The fact that it stands at all today, and is a thriving city, has to do with the very "small" weapon, compared with those in present nuclear arsenals, dropped on it in 1945. Yet we know that Hiroshima, and Nagasaki too, have much to teach us still. A few vignettes of my own encounters in Hiroshima may suggest the kind of knowledge that city can convey to us. The first lesson I learned in Hiroshima, psychologically speaking, was that no one had studied it. I had been naive enough to believe that some individual or group would have looked at the impact on survivors of a weapon everyone knew to have brought about a tragic turning point in human history. But although there had been considerable work on physical aftereffects, psychological consequences had been ignored. On subsequently reflecting on that
The Show
Authors: David H. Balaban
Journal: Annals of Internal Medicine (2009)

On Being a Doctor21 July 2009The ShowDavid H. Balaban, MDDavid H. Balaban, MDFrom Charlottesville Gastroenterology Associates, Charlottesville, VA 22902.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-2-200907070-00013 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The appointment looked innocent enough: “10:30 a.m. Weinstein, Estelle. Follow-up.” I was the new doctor, just out of residency and filling in for a recently departed internist as a locum tenens physician. Usually that meant seeing urgent care patients with little chance of establishing a lasting relationship. As I entered the room, she sat ramrod straight on the examination table.“Hello, Mrs. Weinstein,” I said. “What can I do for you today?”“Such a nice young doctor, Irv!” she exclaimed, turning to her husband seated in the corner. “All my other doctors were so old … they needed a doctor ... Author, Article, and Disclosure InformationAffiliations: From Charlottesville Gastroenterology Associates, Charlottesville, VA 22902.Corresponding Author: David H. Balaban, MD, Charlottesville Gastroenterology Associates, 1139 East High Street, Charlottesville, VA 22902; e-mail, [email protected]net. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 21 July 2009Volume 151, Issue 2Page: 139-140KeywordsElectronic medical recordsEmotionsHerniaIschemiaNursesPainPatientsResidencyThoraxVeins ePublished: 21 July 2009 Issue Published: 21 July 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Temporal patterns of antihypertensive medication use among older adults, 1989 through 1992. An effect of the major clinical trials on clinical practice?
Authors: B. M. Psaty
Journal: JAMA (1995)

<h3>Objective.</h3> —To describe the changing patterns of antihypertensive medication use in the years immediately before and after the publication of the results of three major clinical trials of the treatment of hypertension in older adults. <h3>Design.</h3> —In this cohort study, adults 65 years or older were examined annually on four occasions between June 1989 and May 1992, and the use of antihypertensive medications was assessed by inventory at each visit. The four visits defined the boundaries of three study periods. For each study period, participants receiving antihypertensive therapy were either continuous users (n = 1667, 1643, and 1605, respectively) or starters (n = 157,142,120) of hypertensive therapy. The large clinical trials that convincingly proved the efficacy and safety of low-dose diuretic therapy in older adults were published during the latter parts of period 2 and the early parts of period 3. <h3>Results.</h3> —Among starters, the proportion initiating therapy on diuretics increased from 35.9% in period 2 to 47.5% in period 3, significantly so among women (<i>P</i>=.04). The proportions initiating other drugs displayed no significant trends. Among continuous users, the use of diuretics, β-blockers, and vasodilators generally decreased over the 3-year period, while the use of calcium channel blockers and angiotensin-converting enzyme inhibitors increased significantly in each of the three periods (<i>P</i>&lt;.05). The decline of 2.7% in the prevalence of diuretic use in period 1 abated during period 2 (1.8% decline), and it slowed significantly (<i>P</i>=.03) to almost a complete halt during period 3 (0.2% decline). The rate of increase in the use of calcium channel blockers slowed significantly (<i>P</i>=.01) between period 1 (+6.7%) and period 3 (+2.8%). <h3>Conclusions.</h3> —Although other factors such as cost may have been important, the temporal trends in antihypertensive drug therapy coincided in time with and may have reflected in part the influence of the major clinical trials on the patterns of clinical practice. (<i>JAMA</i>. 1995;273:1436-1438)
Hospitalization trends for paediatric asthma in eastern Finland: a 10-yr survey
Authors: K. Korhonen, T.M. Reijonen, K. Malmström, T. Klaukka, K. Remes, M. Korppi
Journal: European Respiratory Journal (1999)

Although persistent activation of the inspiratory muscles and narrowing of the glottic aperture during expiration have been indicated as relevant mechanisms leading to dynamic hyperinflation in acute asthma, expiratory flow limitation (EFL) has recently been proposed as a possible triggering factor for increasing endexpiratory lung volume (EELV). To establish whether the attainment of maximal flow rate during tidal expiration could elicit dynamic elevation of EELV, breathing pattern, change in EELV by measuring inspiratory capacity (IC) and occurrence of EFL by the negative expiratory pressure (NEP) method were monitored in 10 stable asthmatic subjects during methacholine-induced, progressive bronchoconstriction in seated position. Change in dyspnoea was scored using the Borg scale. At maximum response forced expiratory volume in one second (FEV1) fell on average by 45+/-2% (p&lt;0.001 versus control), while IC decreased 29+/-2%, (by 0.89+/-0.07 L, (p&lt;0.01 versus control)). Only 2 subjects exhibited EFL at the end of methacholine challenge. In 7 subjects EELV started to increase before the occurrence of EFL. Dyspnoea, which increased from 0.2+/-0.1 to 5.5+/-1.0 (Borg scale) at maximum response (p&lt;0.001), was significantly related to the level of bronchoconstriction as assessed by change in (delta)FEV1 (r=0.72; p&lt;0.001) and to dynamic hyperinflation as measured by deltaIC (r=0.50; p&lt;0.001). However, for both deltaFEV1 and deltaIC the slope of the relationship with increasing dyspnoea was highly variable among the subjects. It is concluded that in acute methacholine-induced bronchoconstriction, dynamic hyperinflation may occur in the absence of expiratory flow limitation and that expiratory flow limitation does not represent the triggering factor to generate dynamic hyperinflation. In these circumstances, dyspnoea appears to be related to the increase in end-expiratory lung volume and not to the onset of expiratory flow limitation.
Drugs and highway crashes. Can we separate fact from fancy?
Authors: J. A. Waller
Journal: JAMA (1971)

The use of mind-altering drugs other than alcohol presents a serious contemporary problem. Some people are concerned about the real effects of drugs on users, others about perceived effects which at times seem to bear little relationship to pharmacologic reality. Many are aroused primarily because they see in drug use a symptom of widespread moral and religious decay. A few are worried largely because they fear that drug users may commit acts which harm innocent nonusers. All of these concerns are important in considering the role of mindaltering drugs in the occurrence of highway crashes, because these concerns have largely determined our perception of the problem of drugs and highway crashes. At times, they have led to preventive and corrective actions that not only are inappropriate but often sap away scarce funds and effort that should be devoted to more effective solutions. In this communication the following questions are explored:
Amiodarone in the treatment of refractory ventricular arrhythmias. Importance and safety of initial high-dose therapy
Authors: L. Rakita
Journal: JAMA (1983)

Large initial doses of amiodarone hydrochloride for the treatment of ventricular arrhythmias refractory to conventional therapy were demonstrated to shorten the time to achieve control of the arrhythmia. As compared with a lower-dose regimen, the mean time to achieve partial control (suppression of ventricular tachycardia) was 10.6 ±5.2 days in the highest-dose group (group C), 9.5 ± 6.4 days in the medium-dose group (group B), and 16.9 ±9.1 days in the lowest-dose group (group A). Complete control (suppression of virtually all ventricular ectopy) was similarly earlier in groups B and C (16.1± 7.5 days and 16.0±11.3 days, respectively) as compared with group A (31.0± 10.1 days). The final mean dose for long-term treatment was independent of the initial dose schedule (551 ±245 mg/day; range, 200 to 1,200 mg/day). The large doses were shown to be well tolerated and without serious side effects. (<i>JAMA</i>1983;250:1293-1295)
Schistosomiasis haematobium
Authors: J. Jones
Journal: JAMA (1977)

In our patient, schistosomiasis haematobium was not diagnosed and was treated as a urinary tract infection by several physicians. Physicians are urged to become increasingly aware of the need to recognize strange and exotic diseases normally not present in this country. (<i>JAMA</i>238:1275-1276, 1977)
BOOK REVIEWS
Authors: W. R. FAIR
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article BOOK REVIEWS Get access Current Genitourinary Cancer Surgery . E. David Crawford , Sakti Das , eds. Malvern, Pa : Lea & Febiger , 1990 , 699 pp.$135. WILLIAM R. FAIR WILLIAM R. FAIR Memorial Sloan-Kettering Cancer Center1275 York Ave New York, NY 10021 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 4, 20 February 1991, Page 294, https://doi.org/10.1093/jnci/83.4.294 Published: 20 February 1991
PREVENTION OF CANCER
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Manuscripts Approved for JNCI, August–September 1972
Journal: JNCI Journal of the National Cancer Institute (1972)

Manuscripts Approved for JNCI, August–September 1972 Get access JNCI: Journal of the National Cancer Institute, Volume 49, Issue 4, October 1972, Pages 1216–1217, https://doi.org/10.1093/jnci/49.4.1216-a Published: 01 October 1972
The Doctor's PDA and Smartphone Handbook: Medical Records
Authors: Chris Paton, Mohammad Al-Ubaydli
Journal: Journal of the Royal Society of Medicine (2006)

This is the fifth in a series of extracts from a forthcoming book by M Al-Ubaydli and C Paton. The website [ www.rsmpress.co.uk/bkpda.htm ] includes video tutorials to accompany this text.
Author's reply
Authors: Raphael B. Stricker
Journal: American Journal of Hematology (1988)

We appreciate the continuing worldwide interest in our report [ 11, as evidenced by the letter of Das Gupta et al. and the letter of Miniero and Sacarro [2] that was recently published in your journal.The study of Das Gupta et al. is intriguing and suggests that similar studies should be done in other populations.The letter from Miniero and Sacarro merits further comment.The authors reported ten cases of hematologic malignancy among 4,500 patients with homozygous /3-thalassemia over a 12-year period, for an annual adjusted rate of 17/100,000.Although the annual cancer rate among children in Italy was similar to this, the annual adjusted rate of hematologic malignancy was only 6/100,000 [3].Thus the incidence of hematologic malignancy in homozygous /3thalassemia may be increased, even among children.We were also interested to learn of the study of Quattrin et al. [4] showing that adults with hemoglobin Lepore have an annual rate of hematologic malignancy that is 5-6 times higher than the control rate (by conservative estimate).We agree that caution must be used in interpreting this retrospective data, and that a prospective evaluation would be enlightening.
Symptom burden, quality of life, and distress in acute myeloid leukemia patients receiving induction chemotherapy: A prospective electronic patient-reported outcomes study.
Authors: Thomas William LeBlanc, Steven Wolf, Debra M. Davis, Greg Samsa, Susan C. Locke, Karen E. Steinhauser, Peter A. Ubel, James A. Tulsky, Amy Pickar Abernethy
Journal: Journal of Clinical Oncology (2015)

e20702 Background: Induction chemotherapy for acute myeloid leukemia (AML) is more intensive than many solid tumor treatments, and may be associated with a different symptom burden. Little is known about the most prevalent symptoms during AML induction, nor how they change over time. Methods: We enrolled AML inpatients at initiation of induction chemotherapy, and assessed their symptoms, quality of life (QoL), and distress weekly during their month-long hospitalization for treatment, using 3 validated instruments: Patient Care Monitor v2.0 (PCM); Functional Assessment of Cancer Therapy–Leukemia (FACT-Leu); and NCCN distress thermometer (DT). Here we report updated results from the first 24 patients, using descriptive statistics. Results: Mean age of study participants was 58.7 (SD 12.7). Patients were mostly high-risk for recurrence, with 50% (12) being > 60 years old, 48% (11) having high-risk cytogenetics, and 22% (5) having relapsed disease. Fatigue was the most prevalent symptom, with an average of 64% of patients reporting moderate to severe fatigue across all assessments. The other most prevalent moderate/severe non-functional symptoms were dysgeusia (51%), decreased appetite (44%), dry mouth (43%), diarrhea (38%), insomnia (43%), daytime sleepiness (35%), nausea (33%), hair loss (31%), dry skin (28%), and mouth sores (27%). Median QoL by FACT-Leu decreased substantially between weeks 1 and 2 (118.5 to 107); the largest decrements were in physical well-being and functional well-being (20.5 to 16, and 14 to 11, respectively). QoL by FACT-G did not return to baseline by week 4. Mean DT score at baseline was 5.1, with a trend towards weekly improvements (DT = 3.3 at week 4). Depressive symptoms like hopelessness and sadness were reported by 15% and 16% of patients, respectively. Conclusions: AML patients receiving induction chemotherapy have significant symptom burden, impaired QoL, and moderate psychological distress. The prevalence of these issues suggests sizeable unmet palliative care and psychosocial needs in AML patients receiving induction chemotherapy.
THE TRANSMISSIBILITY OF CANCER.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Preventive Pacemaking
Authors: John A. Kastor
Journal: New England Journal of Medicine (1982)

Although pacemakers have been used clinically for almost 25 years,1 we still do not know in all cases just when to install them. No physician would hesitate to prescribe a permanent pacemaker for a patient with syncope and documented third-degree atrioventricular block. The device will prevent fainting, provide a more physiologic heart rate, and prolong life. But must one wait until a potentially fatal event such as syncope occurs to take definite action?When atrioventricular block develops, some form of heart disease has destroyed the ability of the specialized conducting system to transmit electrical impulses through the atrioventricular node, the . . .
银屑病负担的多维概述
Authors: C.E.M. Griffiths, S.-J. Jo, L. Naldi, R. Romiti, E. Guevara-Sangines, T. Howe, G. Pietri, I. Gilloteau, C. Richardson, H. Tian, M. Augustin
Journal: British Journal of Dermatology (2018)

银屑病是一种常见的慢性炎症性皮肤病,全球有0.09%到11.4%的人口受其困扰。它会造成瘙痒和皮肤疼痛等症状,但实际上,其影响到的不仅仅是皮肤。它通常与其他并发疾病(并存病),比如心血管疾病、银屑病性关节炎(PsA)、肥胖、糖尿病和焦虑或抑郁有关。总而言之,银屑病会对银屑病患者的生活质量(QoL)以及工作效率造成明显的负面影响。此外,常见和困扰症状的存在,比如不同身体部位的瘙痒和银屑病样皮损会进一步增加患者的疾病负担。在这项面向皮肤科医师及其银屑病患者开展的大型跨国调查中,我们估计了并存病、瘙痒和受影响身体部位对患有中度到重度银屑病的患者造成的递增负担。我们利用问卷调查从9个国家(英国、法国、德国、西班牙、意大利、俄罗斯、韩国、墨西哥和巴西)收集了524名皮肤科医师和3821名银屑病患者的匿名反馈并加以分析,评估了银屑病对患者的影响。问卷调查收集了关于银屑病症状(瘙痒存在/程度、瘙痒对睡眠的干扰、皮肤疼痛的存在)、QoL和过去12个月所用医疗资源(例如患者咨询皮肤科医师的次数以及住院治疗次数)的数据。总体来看,结果表明,生理和心理并存病的存在、瘙痒等症状、银屑病性皮损(尤其是头皮、面部、手部等可见部位和生殖器、头皮、面部等敏感部位)会显著影响银屑病患者的QoL,并且会因工作效率降低和医疗资源使用增加而造成重大经济负担。
A case of cholestasis: benign and recurrent and not due to measles
Authors: C. Buffet
Journal: JAMA (1989)

<h3>To the Editor.—</h3> In 1983 we reported in<i>JAMA</i>the case of a 19-year-old man who had a well-documented measles infection and cholestasis.<sup>1</sup>Jaundice appeared a few days after clinical symptoms of rubella. His total bilirubin level increased to 740 μmol/L, while his serum γ-glutamyltransferase level was normal. Endoscopic retrograde cholangiography showed normal biliary ducts. The usual causes of intrahepatic cholestasis were excluded. Histological study of the liver showed major centrolobular cholestasis without necrosis. Jaundice continued for 4 months, but 5 months after the onset results of liver function tests were normal. Rubella seemed to have been the most likely explanation for the cholestasis. This case had a few points in common with that reported by McLellan and Gleiner.<sup>2</sup> Our patient remained in good condition until September 3, 1988, when he developed a pharyngitis. He received 1500 mg/d of troleandomycin. Two days later, troleandomycin therapy was discontinued because
Spinal Pumping
Authors: J. B. Brierley, E. J. Field
Journal: BMJ (1947)

In the surgery of dyspepsia-and surgery is frequently required-it is essential in many cases that pre-operative treat- ment be often long and even trying, and it was this featUire that led me in my search to discover the value of bromide combined with cther aids in the treatment of dyspepsia.-Iam, etc., Dundee.
Vaccinologists Aiming at Less Hurtful "Shots"
Authors: C. Marwick
Journal: JAMA (1998)

THE ACCELERATING PACE of new vaccine development has made incorporating these agents into the childhood immunization schedule a major challenge. In 1989, it took 8 injections to immunize children from birth to 16 years of age; in 1998, the number has nearly doubled: 14 injections are required.